Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Description

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

Conditions

Relapsed or Refractory Multiple Myeloma

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Condition
Relapsed or Refractory Multiple Myeloma
Intervention / Treatment

-

Contacts and Locations

Boston

Dana Farber Cancer institution, Boston, Massachusetts, United States, 02215

New York

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States, 10016

New York

Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute, New York, New York, United States, 10029

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Voluntary participation and signature of informed consent form.
  • 2. ≥18 years of age.
  • 3. Have documented diagnosis of relapsed or refractory multiple myeloma according to Criteria for Response to Multiple Myeloma Treatment(IMWG)diagnostic criteria who have failed all established standard of care.
  • 4. Life expectancy ≥12 weeks.
  • 5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
  • 6. Adequate hematologic, hepatic, and renal function.
  • 1. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy.
  • 2. Active hepatitis B (HBsAg positive and HBV DNA ≥ 1×104 copies/mL or ≥ 2,000 international unit \[IU\]/mL) or hepatitis C (HCV antibody positive and HCV RNA ≥ ULN) infection; participant with HBsAg positive or detective HBV-DNA at screening should receive antiviral treatment as per local practice during the trial.
  • 3. Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
  • 4. Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
  • 5. Active known or suspected autoimmune disease. Participants with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger, type 1 diabetes mellitus (blood glucose can be controlled by insulin therapy) can be included.
  • 6. Current or previous other malignancy within 3 years of study entry, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast.
  • 7. Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
  • 8. Participants with known active infection within 14 days prior to the first SIM0500.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jiangsu Simcere Pharmaceutical Co., Ltd.,

Study Record Dates

2028-12-30